Sounding the alarm on leiomyosarcoma recurrence: role of circulating tumor DNA
Recent work confirms a bench-to-bedside approach that circulating tumor DNA is associated with outcome and objective response to chemotherapy in patients with advanced leiomyosarcoma. Liquid biopsies may be used for risk stratification in future trials guiding treatment decisions by identifying pati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
15 June 2022
|
| In: |
Clinical cancer research
Year: 2022, Jahrgang: 28, Heft: 12, Pages: 2480-2481 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-22-0738 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-22-0738 Verlag, lizenzpflichtig, Volltext: https://aacrjournals.org/clincancerres/article/28/12/2480/699278/Sounding-the-Alarm-on-Leiomyosarcoma-Recurrence 
|
| Verfasserangaben: | Bernd Kasper and Breelyn A. Wilky |
| Zusammenfassung: | Recent work confirms a bench-to-bedside approach that circulating tumor DNA is associated with outcome and objective response to chemotherapy in patients with advanced leiomyosarcoma. Liquid biopsies may be used for risk stratification in future trials guiding treatment decisions by identifying patients who are likely to benefit from chemotherapy.See related article by Madanat-Harjuoja et al., p. 2579 |
|---|---|
| Beschreibung: | Gesehen am 23.01.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-22-0738 |